NCT06054776View on ClinicalTrials.gov

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

October 16, 2026

Study Completion Date

October 16, 2026

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsies

PROCEDURE

Computed Tomography

Undergo PET/CT or CT

PROCEDURE

Echocardiography

Undergo ECHO

BIOLOGICAL

Glofitamab

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

BIOLOGICAL

Obinutuzumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER